Recursion Pharmaceuticals reports $74.7 million revenue for fiscal 2025, up 26.9% year-over-year, amid a $644.8 million net loss.
Recursion Pharmaceuticals (NASDAQ:RXRX) reported nearly $74.7 million in revenue for fiscal 2025, a 26.9% increase year-over-year. The growth reflects expanded strategic collaborations with major biotech firms, including Roche, Bayer, and Merck.
Despite revenue growth, the company posted a net loss of $644.8 million, driven by high infrastructure and operational costs. Recursion’s AI-driven drug discovery platform relies on large-scale computing and partnerships, adding revenue concentration risk.
The company’s focus on oncology, rare diseases, and neuroscience positions it in a competitive biotech sector, though profitability remains elusive amid heavy R&D spending.